Type 2 Transaction (List 1). DOD Biotech Public Company Limited (the “Company”) hereby notifies the significant resolutions passed by the Board of Directors’ Meeting No. 8/2018, held on December 19, 2018
Capital Market Supervisory Board No. Tor Chor. 20/2551 Re: Rules for the Transaction with Significant Acquisition or Disposal of Assets and the Notification of the Board of Governors of the Stock Exchange
partially offset by significant cost increase of secondary raw material. Earnings Analysis 2Q 2018 core EBITDA increased by 63% to $388 million year-on-year.On a portfolio basis, IVL achieved a Core EBITDA
electricity to Industrial Users (IU) 6.9 6.0 6.2 5.6 (0.6) (9.7%) 20.6 24.7 4.1 19.9% Revenue from maintenance service to outside - - - - - - 47.8 - (47.8) N.A.(
bottle, aluminum can to bottling and canning plants which enabled the economies of scales. Furthermore, the successful negotiation with both current and new suppliers has brought down the costs of key raw
and Ft 727.0 806.7 79.7 11.0% FiT Premium 33.2 19.6 (13.6) (41.0%) Sales of electricity to Industrial Users (IU) 6.9 6.8 (0.1) (1.4%) Sales from Biomass Power Plants 767.1 833.1 66.0 8.6% Revenue from
Premium 19.6 14.6 (5.0) (25.5%) Sales of electricity to Industrial Users (IU) 6.8 9.3 2.5 36.8% Sales from Biomass Power Plants 833.1 875.1 42.0 5.0% Revenue from finance lease under a Power Purchase
significant rise to the world’s 3rd highest rank with 86 scores, from No. 15 with 75 scores in the preceding year. Such development was a result of the improvement in the Ease of Shareholder Suits Index
steam boiler and balance of plants including manufacturing and installation 3. Registered Capital: 25,000 EUR or equal to 901,052.50 Baht (Average selling rate on 4th April 2019: 36.0421 Baht per Euro